Search

Your search keyword '"Katus, Hugo A"' showing total 31 results
Start Over Author "Katus, Hugo A" Language undetermined
31 results on '"Katus, Hugo A"'

1. Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?

Author

Israel, Carsten, Staudacher, Ingo, Leclercq, Christophe, Botto, Giovanni Luca, Scherr, Daniel, Fach, Andreas, Duru, Firat, Zylla, Maura M, Katus, Hugo A, Thomas, Dierk, Children’s Center Bethel (EvkB), Heidelberg University Hospital [Heidelberg], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Medical University Graz, Universität Zürich [Zürich] = University of Zurich (UZH), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Projekt DEAL, University of Zurich, Thomas, Dierk, and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Electric Countershock, 610 Medicine & health, Ventricular tachycardia, General Medicine, 2705 Cardiology and Cardiovascular Medicine, Implantable cardioverter-defibrillator, Defibrillators, Implantable, Wearable Electronic Devices, Sudden cardiac death, Myocardial infarction, Death, Sudden, Cardiac, 10209 Clinic for Cardiology, Humans, [SDV.IB]Life Sciences [q-bio]/Bioengineering, cardiovascular diseases, Wearable cardioverter-defibrillator, Cardiomyopathies, Cardiology and Cardiovascular Medicine, Defibrillators, Randomized Controlled Trials as Topic
Abstract

Sudden cardiac death (SCD) is the most frequent cause of cardiovascular death in industrialized nations. Patients with cardiomyopathy are at increased risk for SCD and may benefit from an implantable cardioverter-defibrillator (ICD). The risk of SCD is highest in the first months after myocardial infarction or first diagnosis of severe non-ischemic cardiomyopathy. On the other hand, left ventricular function may improve in a subset of patients to such an extent that an ICD might no longer be needed. To offer protection from a transient risk of SCD, the wearable cardioverter-defibrillator (WCD) is available. Results of the first randomized clinical trial investigating the role of the WCD after myocardial infarction were recently published. This review is intended to provide insight into data from the VEST trial, and to put these into perspective with studies and clinical experience. As a non-invasive, temporary therapy, the WCD may offer advantages over early ICD implantation. However, recent data demonstrate that patient compliance and education play a crucial role in this new concept of preventing SCD.

Published
2022

2. Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial

Author

Hjort, Marcus, Eggers, Kai M., Ghukasyan Lakic, Tatevik, Lindbäck, Johan, Budaj, Andrzej, Cornel, Jan H., Giannitsis, Evangelos, Katus, Hugo A., Siegbahn, Agneta, Storey, Robert F., Becker, Richard C., Wallentin, Lars, and Lindahl, Bertil

Subjects
MINOCA, All institutes and research themes of the Radboud University Medical Center, patofysiologi, Kardiologi, myocardial infarction, biomarkers, pathophysiology, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], hjärtinfarkt, Cardiac and Cardiovascular Systems, Cardiology and Cardiovascular Medicine, biomarkörer
Abstract

Background The pathobiology of myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA) is often uncertain. Investigating biomarker concentrations and their changes may offer novel pathophysiological insights. Methods and Results In this post hoc study of the PLATO (Platelet Inhibition and Patient Outcomes) trial, concentrations of hs‐cTnT (high‐sensitivity cardiac troponin T), NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), hs‐CRP (high‐sensitivity C‐reactive protein), and GDF‐15 (growth differentiation factor 15) were measured in patients with MINOCA at baseline (n=554) and at 1‐month follow‐up (n=107). For comparisons, biomarkers were also measured in patients with MI with obstructive (stenosis ≥50%) coronary artery disease (baseline: n=11 106; follow‐up: n=2755]). Adjusted linear regression models were used to compare concentrations and their short‐ and long‐term changes. The adjusted geometric mean ratios (GMRs) in patients with MINOCA (median age, 61 years; 50.4% women) indicated lower hs‐cTnT (GMR, 0.77 [95% CI, 0.68–0.88]) but higher hs‐CRP (GMR, 1.21 [95% CI, 1.08–1.37]) and GDF‐15 concentrations (GMR, 1.06 [95% CI, 1.02–1.11]) at baseline compared with patients with MI with obstructive coronary artery disease, whereas NT‐proBNP concentrations were similar. Temporal decreases in hs‐cTnT, NT‐proBNP, and hs‐CRP concentrations until 1‐month follow‐up were more pronounced in patients with MINOCA. At follow‐up, patients with MINOCA had lower concentrations of hs‐cTnT (GMR, 0.71 [95% CI, 0.60–0.84]), NT‐proBNP (GMR, 0.45 [95% CI, 0.36–0.56]), and hs‐CRP (GMR, 0.68 [95% CI, 0.53–0.86]). One‐month GDF‐15 concentrations were similar between both groups with MI. Conclusions Biomarker concentrations suggest greater initial inflammatory activity, similar degree of myocardial dysfunction, and less pronounced myocardial injury during the acute phase of MINOCA compared with MI with obstructive coronary artery disease but also faster myocardial recovery. Registration URL: http://www.clinicaltrials.gov ; Unique identifier: NCT00391872.

Published
2023

4. Identification of Specific Coronary Artery Disease Phenotypes Implicating Differential Pathophysiologies

Author

Krohn, Jona B., Nguyen, Y Nhi, Akhavanpoor, Mohammadreza, Erbel, Christian, Domschke, Gabriele, Linden, Fabian, Kleber, Marcus E., Delgado, Graciela, März, Winfried, Katus, Hugo A., and Gleissner, Christian A.

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Background and AimsThe roles of multiple risk factors of coronary artery disease (CAD) are well established. Commonly, CAD is considered as a single disease entity. We wish to examine whether coronary angiography allows to identify distinct CAD phenotypes associated with major risk factors and differences in prognosis.MethodsIn a cohort of 4,344 patients undergoing coronary angiography at Heidelberg University Hospital between 2014 and 2016, cluster analysis of angiographic reports identified subgroups with similar patterns of spatial distribution of high-grade stenoses. Clusters were independently confirmed in 3,129 patients from the LURIC study.ResultsFour clusters were identified: cluster one lacking critical stenoses comprised the highest percentage of women with the lowest cardiovascular risk. Patients in cluster two exhibiting high-grade stenosis of the proximal RCA had a high prevalence of the metabolic syndrome, and showed the highest levels of inflammatory biomarkers. Cluster three with predominant proximal LAD stenosis frequently presented with acute coronary syndrome and elevated troponin levels. Cluster four with high-grade stenoses throughout had the oldest patients with the highest overall cardiovascular risk. All-cause and cardiovascular mortality differed significantly between the clusters.ConclusionsWe identified four phenotypic subgroups of CAD bearing distinct demographic and biochemical characteristics with differences in prognosis, which may indicate multiple disease entities currently summarized as CAD.

Published
2021

5. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)

Author

Brugada, Josep, Katritsis, Demosthenes, Arbelo, Elena, Arribas, Fernando, Bax, Jeroen, Blomström-Lundqvist, Carina, Calkins, Hugh, Corrado, Domenico, Deftereos, Spyridon, Diller, Gerhard-Paul, Gomez-Doblas, Juan, Gorenek, Bulent, Grace, Andrew, Ho, Siew Yen, Kaski, Juan-Carlos, Kuck, Karl-Heinz, Lambiase, Pier David, Sacher, Frederic, Sarquella-Brugada, Georgia, Suwalski, Piotr, Zaza, Antonio, De Potter, Tom, Sticherling, Christian, Basso, Cristina, Bocchiardo, Mario, Budts, Werner, Dobrev, Dobromir, Gevaert, Sofie, Heidbuchel, Hein, Kanagaratnam, Prapa, Kriebel, Thomas, Lancellotti, Patrizio, Lopatin, Yury, Merkely, Béla, Paul, Thomas, Pavlović, Nikola, Potpara, Tatjana, Scherr, Daniel, Zeppenfeld, Katja, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean-Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris, Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo, Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil, Merkely, Bela, Mueller, Christian, Petersen, Steffen, Petronio, Anna Sonia, Richter, Dimitrios, Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain, Sousa-Uva, Miguel, Touyz, Rhian, Amara, Walid, Grigoryan, Svetlana, Podczeck-Schweighofer, Andrea, Chasnoits, Alexandr, Vandekerckhove, Yves, Sokolovich, Sekib, Traykov, Vassil, Skoric, Bosko, Papasavvas, Elias, Kautzner, Josef, Riahi, Sam, Kampus, Priit, Parikka, Hannu, Piot, Olivier, Etsadashvili, Kakhaber, STELLBRINK, CHRISTOPH, Manolis, Antonis, Csanádi, Zoltán, Gudmundsson, Kristjan, Erwin, John, Barsheshet, Alon, De Ponti, Roberto, Abdrakhmanov, Ayan, Jashari, Haki, Lunegova, Olga, Jubele, Kristine, Refaat, Marwan, Puodziukynas, Aras, Groben, Laurent, Grosu, Aurel, Pavlovic, Nikola, Ibtissam, Fellat, Trines, Serge, Poposka, Lidija, Haugaa, Kristina, Kowalski, Oskar, Cavaco, Diogo, Dobreanu, Dan, Mikhaylov, Evgeny, Zavatta, Marco, Nebojša, Mujović, Hlivak, Peter, Ferreira-Gonzalez, Ignacio, Juhlin, Tord, Reichlin, Tobias, Haouala, Habib, Akgun, Taylan, Gupta, Dhiraj, IHU-LIRYC, and Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]

Subjects
Tachycardia, pre-excitation, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, focal, [SDV]Life Sciences [q-bio], Cardiology, Guidelines, 030204 cardiovascular system & hematology, tachycardia, arrhythmia, ablation, atrioventricular, flutter, junctional, macro–re-entrant, nodal, re-entrant, supraventricular, Electrocardiography, 03 medical and health sciences, 0302 clinical medicine, Tachycardia, Supraventricular, medicine, Humans, cardiovascular diseases, ComputingMilieux_MISCELLANEOUS, reproductive and urinary physiology, Task force, business.industry, Arrhythmias, Cardiac, 030229 sport sciences, medicine.disease, 3. Good health, EBSTEIN ANOMALY, embryonic structures, Emergency medicine, Catheter Ablation, cardiovascular system, Re entrant, Supraventricular tachycardia, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract

2019 ESC Guidelines for the management of patients with supraventricular tachycardia : The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)

Published
2019

6. Major Bleeding of Transjugular Native Kidney Biopsies. A French Nationwide Cohort Study

Author

Hindricks, Gerhard, Potpara, Tatjana, Dagres, Nikolaos, Arbelo, Elena, Bax, Jeroen, Blomström-Lundqvist, Carina, Boriani, Giuseppe, Castella, Manuel, Dan, Gheorghe-Andrei, Dilaveris, Polychronis, Fauchier, Laurent, Filippatos, Gerasimos, Kalman, Jonathan, La Meir, Mark, Lane, Deirdre, Lebeau, Jean-Pierre, Lettino, Maddalena, Lip, Gregory, Pinto, Fausto, Thomas, G Neil, Valgimigli, Marco, van Gelder, Isabelle, van Putte, Bart, Watkins, Caroline, Kirchhof, Paulus, Kühne, Michael, Aboyans, Victor, Ahlsson, Anders, Balsam, Pawel, Bauersachs, Johann, Benussi, Stefano, Brandes, Axel, Braunschweig, Frieder, Camm, a John, Capodanno, Davide, Casadei, Barbara, Conen, David, Crijns, Harry, Delgado, Victoria, Dobrev, Dobromir, Drexel, Heinz, Eckardt, Lars, Fitzsimons, Donna, Folliguet, Thierry, Gale, Chris, Gorenek, Bulent, Haeusler, Karl Georg, Heidbuchel, Hein, Iung, Bernard, Katus, Hugo, Kotecha, Dipak, Landmesser, Ulf, Leclercq, Christophe, Lewis, Basil, Mascherbauer, Julia, Merino, Jose Luis, Merkely, Béla, Mont, Lluís, Mueller, Christian, Nagy, Klaudia, Oldgren, Jonas, Pavlović, Nikola, Pedretti, Roberto, Petersen, Steffen, Piccini, Jonathan, Popescu, Bogdan, Pürerfellner, Helmut, Richter, Dimitrios, Roffi, Marco, Rubboli, Andrea, Scherr, Daniel, Schnabel, Renate, Simpson, Iain, Shlyakhto, Evgeny, Sinner, Moritz, Steffel, Jan, Sousa-Uva, Miguel, Suwalski, Piotr, Svetlosak, Martin, Touyz, Rhian, Neil Thomas, G, Delassi, Tahar, Sisakian, Hamayak, Chasnoits, Alexandr, Pauw, Michel De, Smajić, Elnur, Shalganov, Tchavdar, Avraamides, Panayiotis, Kautzner, Josef, Gerdes, Christian, Alaziz, Ahmad Abd, Kampus, Priit, Raatikainen, Pekka, Boveda, Serge, Papiashvili, Giorgi, Vassilikos, Vassilios, Csanádi, Zoltán, Arnar, David, Galvin, Joseph, Barsheshet, Alon, Caldarola, Pasquale, Rakisheva, Amina, Bytyçi, Ibadete, Kerimkulova, Alina, Kalejs, Oskars, Njeim, Mario, Puodziukynas, Aras, Groben, Laurent, Sammut, Mark, Grosu, Aurel, Boskovic, Aneta, Moustaghfir, Abdelhamid, Groot, Natasja De, Poposka, Lidija, Anfinsen, Ole-Gunnar, Mitkowski, Przemyslaw, Cavaco, Diogo Magalhães, Siliste, Calin, Mikhaylov, Evgeny, Bertelli, Luca, Kojic, Dejan, Hatala, Robert, Fras, Zlatko, Arribas, Fernando, Juhlin, Tord, Sticherling, Christian, Abid, Leila, Atar, Ilyas, Sychov, Oleg, Bates, Matthew, Zakirov, Nodir, Halimi, Jean-Michel, Gatault, Philippe, Longuet, Hélène, Barbet, Christelle, Goumard, Annabelle, Gueguen, Juliette, Goin, Nicolas, Sautenet, Bénédicte, Herbert, Julien, Bisson, Arnaud, Universität Leipzig [Leipzig], University of Belgrade [Belgrade], Leiden University Medical Center (LUMC), Uppsala University, Università degli Studi di Modena e Reggio Emilia, Colentina University Hospital, University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), National and Kapodistrian University of Athens (NKUA), Université d'Athènes (UOA), Attikon University Hospital, The Royal Melbourne Hospital, University of Liverpool, San Gerardo Hospital of Monza, Aalborg University [Denmark] (AAU), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Faculdade de Medicina [Lisboa], Universidade de Lisboa (ULISBOA), Hospital de Santa Maria [Lisboa], Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, and Université de Nantes (UN)-Université de Nantes (UN)

Subjects
medicine.medical_specialty, Framingham Risk Score, Percutaneous, business.industry, medicine.medical_treatment, kidney biopsy, Retrospective cohort study, Odds ratio, Lower risk, medicine.disease, transjugular, Nephrectomy, Surgery, [SHS]Humanities and Social Sciences, bleeding score, Hematoma, percutaneous, Nephrology, Clinical Research, medicine, epidemiology, business, ComputingMilieux_MISCELLANEOUS, Cohort study
Abstract

Introduction The risk of bleeding associated with transjugular kidney biopsies is unclear, and which patients are the best candidates for this route is unknown. Methods This was a retrospective cohort study comparing proportion of bleeding associated with transjugular versus percutaneous native kidney biopsies in all patients in France in the 2010–2019 period. Major bleeding at day 8 (i.e., blood transfusions, hemorrhage/hematoma, angiographic intervention, nephrectomy) and risk of death at day 30 were assessed, and we used a bleeding risk score initially developed for the percutaneous route. Results Our analysis included 60,331 patients (transjugular route: 5305; percutaneous route: 55,026 patients). The observed proportion of major bleeding varied widely (transjugular vs. percutaneous): 0.4% versus 0.5% for the lowest risk scores (0–4) to 19.1% versus 30.8% for the highest risk scores (≥35). Transjugular was more frequently used than percutaneous route (39% vs. 24%) when the risk score was ≥20 (15,133/60,331; 25% of all patients). Transjugular was associated with a lower risk of major bleeding than percutaneous route in multivariate analyses (odds ratio [OR]: 0.88 [0.78–0.99]), especially for scores ≥20 (OR: 0.83 [0.72–0.96], (i.e., 25% of patients). Major bleeding was associated with an increased risk of death both for transjugular (OR: 1.77 [1.00–3.14]) and percutaneous (OR: 1.80 [1.43–2.28]) routes. Conclusions The transjugular route is independently associated with a lower risk of bleeding than the percutaneous route, especially in high-risk patients identified by a preprocedure risk score ≥20 (i.e., 25% of patients). Major bleeding is associated with an increased risk of death for both routes., Graphical abstract

Published
2021

7. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Author

Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak, Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris, Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil, Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans, Sibbing, Dirk, Siontis, George, Kastrati, Adnan, Mamas, Mamas, Aboyans, Victor, Angiolillo, Dominick, Bueno, Hector, Bugiardini, Raffaele, Byrne, Robert, Castelletti, Silvia, Chieffo, Alaide, Cornelissen, Veronique, Crea, Filippo, Delgado, Victoria, Drexel, Heinz, Gierlotka, Marek, Halvorsen, Sigrun, Haugaa, Kristina Hermann, Jankowska, Ewa, Katus, Hugo, Kinnaird, Tim, Kluin, Jolanda, Kunadian, Vijay, Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Meinila, Leena, Mylotte, Darren, Ndrepepa, Gjin, Omerovic, Elmir, Pedretti, Roberto, Petersen, Steffen, Petronio, Anna Sonia, Pontone, Gianluca, Popescu, Bogdan, Potpara, Tatjana, Ray, Kausik, Luciano, Flavio, Richter, Dimitrios, Shlyakhto, Evgeny, Simpson, Iain, Sousa-Uva, Miguel, Storey, Robert, Touyz, Rhian, Valgimigli, Marco, VRANCKX, PASCAL, Yeh, Robert, Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak L, Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris P, Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil S, Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans H, Sibbing, Dirk, Siontis, George C M, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Collet J.-P., Thiele H., Barbato E., Bauersachs J., Dendale P., Edvardsen T., Gale C.P., Jobs A., Lambrinou E., Mehilli J., Merkely B., Roffi M., Sibbing D., Kastrati A., Mamas M.A., Aboyans V., Angiolillo D.J., Bueno H., Bugiardini R., Byrne R.A., Castelletti S., Chieffo A., Cornelissen V., Crea F., Delgado V., Drexel H., Gierlotka M., Halvorsen S., Haugaa K.H., Jankowska E.A., Katus H.A., Kinnaird T., Kluin J., Kunadian V., Landmesser U., Leclercq C., Lettino M., Meinila L., Mylotte D., Ndrepepa G., Omerovic E., Pedretti R.F.E., Petersen S.E., Petronio A.S., Pontone G., Popescu B.A., Potpara T., Ray K.K., Luciano F., Richter D.J., Shlyakhto E., Simpson I.A., Sousa-Uva M., Storey R.F., Touyz R.M., Valgimigli M., Vranckx P., Yeh R.W., Barthelemy O., Bhatt D.L., Dorobantu M., Folliguet T., Gilard M., Juni P., Lewis B.S., Meliga E., Mueller C., Rutten F.H., and Siontis G.C.M.

Subjects
unstable angina, Myocardial ischaemia, [SDV]Life Sciences [q-bio], Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], dual antithrombotic therapy, Guideline, heparin, 030204 cardiovascular system & hematology, Platelet inhibition, antiplatelet, 0302 clinical medicine, ST segment, Medicine, dabigatran, Myocardial infarction, guidelines, glycoprotein iib/iiia inhibitors, anticoagulation, Non-ST Elevated Myocardial Infarction, rivaroxaban, ComputingMilieux_MISCELLANEOUS, reproductive and urinary physiology, diabetes, bleedings, bivalirudin, atherothrombosi, Disease Management, angioplasty, Guidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable angina, enoxaparin, General Medicine, Clopidogrel, 3. Good health, early invasive strategy, myocardial infarction, triple therapy, 030220 oncology & carcinogenesis, High sensitivity troponin, embryonic structures, Cardiology, Platelet aggregation inhibitor, revascularization, biological phenomena, cell phenomena, and immunity, Cardiology and Cardiovascular Medicine, Ticagrelor, medicine.drug, Human, recommendation, Acute coronary syndrome, medicine.medical_specialty, aspirin, glycoprotein IIb/IIIa inhibitor, non-ST-elevation myocardial infarction, apixaban, rhythm monitoring, European Society of Cardiology, ticagrelor, 03 medical and health sciences, nitrate, atherothrombosis, betablockers, Internal medicine, acute cardiac care, minoca, chest pain unit, Diseases of the circulatory (Cardiovascular) system, Humans, In patient, Acute Coronary Syndrome, clopidogrel, Unstable angina, urogenital system, nitrates, business.industry, fondaparinux, betablocker, Arrhythmias, Cardiac, 030229 sport sciences, bleeding, medicine.disease, myocardial ischaemia, platelet inhibition, prasugrel, diabete, Glycoprotein IIb/IIIa inhibitors, RC666-701, bypass surgery, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, recommendations, edoxaban, high-sensitivity troponin, stent, business, Platelet Aggregation Inhibitors, cangrelor
Abstract

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Published
2021
Full Text
View/download PDF

8. Additional file 1 of Myocardial mechanics in dilated cardiomyopathy: prognostic value of left ventricular torsion and strain

Author

Ochs, Andreas, Riffel, Johannes, Ochs, Marco M., Arenja, Nisha, Fritz, Thomas, Galuschky, Christian, Schuster, Andreas, Bruder, Oliver, Mahrholdt, Heiko, Giannitsis, Evangelos, Frey, Norbert, Katus, Hugo A., Buss, Sebastian J., and Andr��, Florian

Subjects
cardiovascular system, cardiovascular diseases
Abstract

Additional file 1: Table S1. Correlation matrix for correlation coefficients (r) of common CMR and strain parameters including LV torsion. LVEF: left ventricular ejection fraction; GLS: global longitudinal strain; GCS: global circumferential strain; GRS: global radial strain; LV torsion: left ventricular torsion; LVEDV: left ventricular end-diastolic volume. Table S2. Univariate survival analysis of the secondary endpoint (Cox proportional-hazards regression). HR: hazard ratio; CI: confidence interval; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; NT-pro BNP: N-terminal pro-hormone brain natriuretic peptide; LGE: late gadolinium enhancement; GLS: global longitudinal strain; GCS: global circumferential strain; GRS: global radial strain. Table S3. Multivariate survival analysis of the secondary endpoint (Cox proportional-hazards regression). HR: hazard ratio; CI: confidence interval; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LGE: late gadolinium enhancement; GLS: global longitudinal strain; GCS: global circumferential strain; GRS: global radial strain. Table S4a. Intra- and Interobserver variability of the strain parameters in healthy individuals. ICC: intra-class correlation coefficient; CI: confidence interval; GLS: global longitudinal strain; GCS: global circumferential strain; GRS: global radial strain; LV: left ventricular. Table S4b. Intra- and Interobserver variability of the strain parameters in DCM patients. ICC: intra-class correlation coefficient; CI: confidence interval; GLS: global longitudinal strain; GCS: global circumferential strain; GRS: global radial strain; LV: left ventricular.

Published
2021
Full Text
View/download PDF

9. Additional file 2 of Myocardial mechanics in dilated cardiomyopathy: prognostic value of left ventricular torsion and strain

Author

Ochs, Andreas, Riffel, Johannes, Ochs, Marco M., Arenja, Nisha, Fritz, Thomas, Galuschky, Christian, Schuster, Andreas, Bruder, Oliver, Mahrholdt, Heiko, Giannitsis, Evangelos, Frey, Norbert, Katus, Hugo A., Buss, Sebastian J., and Andr��, Florian

Subjects
cardiovascular system, cardiovascular diseases, musculoskeletal system, circulatory and respiratory physiology
Abstract

Additional file 2: Figure S1. Kaplan���Meier analysis of a CMR risk score for the prediction of the secondary endpoint. CMR risk score is based on different CMR (LVEF, LGE) and strain parameters for the prediction of the secondary endpoint in DCM patients. Cut-off values as mentioned in Fig. 4: low risk (0-1p), intermediate risk (2-5p) and high risk (6p). CMR: cardiac magnetic resonance imaging; DCM: dilated cardiomyopathy; GLS: global longitudinal strain; GCS: global circumferential strain; GRS: global radial strain; LVEF: left ventricular ejection fraction; LGE: late gadolinium enhancement. Figure S2. Kaplan���Meier analysis of a simplified CMR risk score in DCM patients. The simplified CMR risk score is based on LVEF, LGE and GLS as the single strain parameter for the prediction of the primary endpoint (cut-off values as mentioned in Fig. 4 of the manuscript): low risk (0-2p) and high risk (3p). CMR: cardiac magnetic resonance imaging; DCM: dilated cardiomyopathy; LGE: late gadolinium enhancement; LVEF: left ventricular ejection fraction; GLS: global longitudinal strain.

Published
2021
Full Text
View/download PDF

10. Additional file 1 of Presence of contractile impairment appears crucial for structural remodeling in idiopathic left bundle-branch block

Author

Salatzki, Janek, Fischer, Theresa, Riffel, Johannes, André, Florian, Hirschberg, Kristóf, Ochs, Andreas, Hund, Hauke, Müller-Hennessen, Matthias, Giannitsis, Evangelos, Friedrich, Matthias G., Scholz, Eberhard, Frey, Norbert, Katus, Hugo A., and Ochs, Marco

Subjects
Data_FILES
Abstract

Additional file 1. Additional tables.

Published
2021
Full Text
View/download PDF

11. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Author

Ibanez, Borja, James, Stefan, Agewall, Stefan, Antunes, Manuel J., Bucciarelli-Ducci, Chiara, Bueno, Hector, Caforio, Alida L. P., Crea, Filippo, Goudevenos, John A., Halvorsen, Sigrun, Hindricks, Gerhard, Kastrati, Adnan, Lenzen, Mattie J., Prescott, Eva, Roffi, Marco, Valgimigli, Marco, Varenhorst, Christoph, Vranckx, Pascal, Widimský, Petr, Baumbach, Andreas, Bugiardini, Raffaele, Coman, Ioan Mircea, Delgado, Victoria, Fitzsimons, Donna, Gaemperli, Oliver, Gershlick, Anthony H., Gielen, Stephan, Harjola, Veli-Pekka, Katus, Hugo A., Knuuti, Juhani, Kolh, Philippe, Leclercq, Christophe, Lip, Gregory Y. H., Morais, Joao, Neskovic, Aleksandar N., Neumann, Franz-Josef, Niessner, Alexander, Piepoli, Massimo Francesco, Richter, Dimitrios J., Shlyakhto, Evgeny, Simpson, Iain A, Steg, Ph Gabriel, Terkelsen, Christian Juhl, Thygesen, Kristian, Windecker, Stephan, Zamorano, Jose Luis, Zeymer, Uwe, Ibanez, Borja, James, Stefan, Agewall, Stefan, Antunes, Manuel J., Bucciarelli-Ducci, Chiara, Bueno, Hector, Caforio, Alida L. P., Crea, Filippo, Goudevenos, John A., Halvorsen, Sigrun, Hindricks, Gerhard, Kastrati, Adnan, Lenzen, Mattie J., Prescott, Eva, Roffi, Marco, Valgimigli, Marco, Varenhorst, Christoph, Vranckx, Pascal, Widimskã½, Petr, Baumbach, Andrea, Bugiardini, Raffaele, Coman, Ioan Mircea, Delgado, Victoria, Fitzsimons, Donna, Gaemperli, Oliver, Gershlick, Anthony H., Gielen, Stephan, Harjola, Veli-Pekka, Katus, Hugo A., Knuuti, Juhani, Kolh, Philippe, Leclercq, Christophe, Lip, Gregory Y. H., Morais, Joao, Neskovic, Aleksandar N., Neumann, Franz-Josef, Niessner, Alexander, Piepoli, Massimo Francesco, Richter, Dimitrios J., Shlyakhto, Evgeny, Simpson, Iain A, Steg, Ph Gabriel, Terkelsen, Christian Juhl, Thygesen, Kristian, Windecker, Stephan, Zamorano, Jose Lui, and Zeymer, Uwe

Subjects
Quality indicator, medicine.medical_treatment, Quality indicators, Guideline, ST-segment elevation, 030204 cardiovascular system & hematology, 0302 clinical medicine, ST segment, 030212 general & internal medicine, Myocardial infarction, reproductive and urinary physiology, Emergency medical system, Evidence, Risk assessment, MINOCA, Ischaemic heart disease, Fibrinolysis, Secondary prevention, Primary percutaneous coronary intervention, Reperfusion therapy, Antithrombotics, embryonic structures, Cardiology, Acute coronary syndrome, biological phenomena, cell phenomena, and immunity, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Acute myocardial infarction, Acute coronary syndromes, Guidelines, Antithrombotic therapy, 03 medical and health sciences, Antithrombotic, Internal medicine, medicine, Fibrinolysi, In patient, cardiovascular diseases, urogenital system, Task force, business.industry, medicine.disease, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, business
Abstract

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

Published
2017

12. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

Author

Aboyans, Victor, Ricco, Jean-Baptiste, Bartelink, Marie-Louise E. L., Björck, Martin, Brodmann, Marianne, Cohnert, Tina, Collet, Jean-Philippe, Czerny, Martin, De Carlo, Marco, Debus, Sebastian, Espinola-Klein, Christine, Kahan, Thomas, Kownator, Serge, Mazzolai, Lucia, Naylor, A Ross, Roffi, Marco, Röther, Joachim, Sprynger, Muriel, Tendera, Michal, Tepe, Gunnar, Venermo, Maarit, Vlachopoulos, Charalambos, Desormais, Ileana, Widimsky, Petr, Kolh, Philippe, Agewall, Stefan, Bueno, Héctor, Coca, Antonio, De Borst, Gert J., Delgado, Victoria, Dick, Florian, Erol, Cetin, Ferrini, Marc, Kakkos, Stavros, Katus, Hugo A., Knuuti, Juhani, Lindholt, Jes, Mattle, Heinrich, Pieniazek, Piotr, Piepoli, Massimo Francesco, Scheinert, Dierk, Sievert, Horst, Simpson, Iain, Sulzenko, Jakub, Tamargo, Juan, Tokgozoglu, Lale, Torbicki, Adam, Tsakountakis, Nikolaos, Tuñón, José, De Ceniga, Melina Vega, Windecker, Stephan, Zamorano, Jose Luis, Barbato, Emanuele, Coman, Ioan Mircea, Dean, Veronica, Fitzsimons, Donna, Gaemperli, Oliver, Hindricks, Gerhard, Iung, Bernard, Juni, Peter, Lancellotti, Patrizio, Leclercq, Christophe, McDonagh, Theresa, Ponikowski, Piotr, Richter, Dimitrios J., Shlyakhto, Evgeny, Simpson, Iain A., Zelveian, Parounak H., Haumer, Markus, Isachkin, Dzmitry, De Backer, Tine, Dilic, Mirza, Petrov, Ivo, Kirhmajer, Majda Vrkic, Karetova, Debora, Prescott, Eva, Soliman, Hamdy, Paapstel, Ants, Makinen, Kimmo, Tosev, Slavco, Messas, Emmanuel, Pagava, Zurab, Müller, Oliver J., Naka, Katerina K., Járai, Zoltán, Gudjonsson, Thorbjorn, Jonas, Michael, Novo, Salvatore, Ibrahimi, Pranvera, Lunegova, Olga, Dzerve, Vilnis, Misonis, Nerijus, Beissel, Jean, Pllaha, Elton, Taberkant, Mustapha, Bakken, Torbjørn, Teles, Rui, Lighezan, Daniel, Konradi, Alexandra, Zavatta, Marco, Madaric, Juraj, Fras, Zlatko, Melchor, Lorenzo Silva, Näslund, Ulf, Amann-Vesti, Beatrice, Obiekezie, Agu, Aboyans, Victor, Ricco, Jean-Baptiste, Bartelink, Marie-Louise E.L., Björck, Martin, Brodmann, Marianne, Cohnert, Tina, Collet, Jean-Philippe, Czerny, Martin, De Carlo, Marco, Debus, Sebastian, Espinola-Klein, Christine, Kahan, Thoma, Kownator, Serge, Mazzolai, Lucia, Naylor, A Ro, Roffi, Marco, Röther, Joachim, Sprynger, Muriel, Tendera, Michal, Tepe, Gunnar, Venermo, Maarit, Vlachopoulos, Charalambo, Desormais, Ileana, Widimsky, Petr, Kolh, Philippe, Agewall, Stefan, Bueno, Héctor, Coca, Antonio, De Borst, Gert J., Delgado, Victoria, Dick, Florian, Erol, Cetin, Ferrini, Marc, Kakkos, Stavro, Katus, Hugo A., Knuuti, Juhani, Lindholt, Je, Mattle, Heinrich, Pieniazek, Piotr, Piepoli, Massimo Francesco, Scheinert, Dierk, Sievert, Horst, Simpson, Iain, Sulzenko, Jakub, Tamargo, Juan, Tokgozoglu, Lale, Torbicki, Adam, Tsakountakis, Nikolao, Tuñón, José, De Ceniga, Melina Vega, Windecker, Stephan, Zamorano, Jose Lui, Barbato, Emanuele, Coman, Ioan Mircea, Dean, Veronica, Fitzsimons, Donna, Gaemperli, Oliver, Hindricks, Gerhard, Iung, Bernard, Juni, Peter, Lancellotti, Patrizio, Leclercq, Christophe, McDonagh, Theresa, Ponikowski, Piotr, Richter, Dimitrios J., Shlyakhto, Evgeny, Simpson, Iain A., Zelveian, Parounak H., Haumer, Marku, Isachkin, Dzmitry, De Backer, Tine, Dilic, Mirza, Petrov, Ivo, Kirhmajer, Majda Vrkic, Karetova, Debora, Prescott, Eva, Soliman, Hamdy, Paapstel, Ant, Makinen, Kimmo, Tosev, Slavco, Messas, Emmanuel, Pagava, Zurab, Müller, Oliver J., Naka, Katerina K., Járai, Zoltán, Gudjonsson, Thorbjorn, Jonas, Michael, Novo, Salvatore, Ibrahimi, Pranvera, Lunegova, Olga, Dzerve, Vilni, Misonis, Neriju, Beissel, Jean, Pllaha, Elton, Taberkant, Mustapha, Bakken, Torbjørn, Teles, Rui, Lighezan, Daniel, Konradi, Alexandra, Zavatta, Marco, Madaric, Juraj, Fras, Zlatko, Melchor, Lorenzo Silva, Näslund, Ulf, Amann-Vesti, Beatrice, and Obiekezie, Agu

Subjects
medicine.medical_specialty, Carotid artery disease, business.industry, Atherosclerotic disease, Upper extremity artery disease, Guideline, 030204 cardiovascular system & hematology, Vascular surgery, Lower extremity artery disease, Multisite artery disease, Peripheral Arterial Diseases, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Renal artery disease, Internal medicine, Peripheral arterial disease, medicine, Cardiology, Mesenteric artery disease, 030212 general & internal medicine, Vertebral artery disease, Cardiology and Cardiovascular Medicine, business
Abstract

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries

Published
2017

13. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial

Author

Franchi, Francesco, James, Stefan, Ghukasyan, Tatevik, Budaj, Andrzej J., Cornel, Jan H., Katus, Hugo A., Keltai, Matyas, Kontny, Frederic, Lewis, Basil S., Storey, Robert F., Himmelmann, Anders, Wallentin, Lars, Angiolillo, Dominick J., Parkhomenko, Alexander Nikolaevich, Oto, Ali, Skene, Allan, Budaj, Andrzej, Freij, Anneli, Santoso, Anwar, Armando, A, Meier, Bernhard, Yu, Cheuk Man, Cannon, Christopher P., Zambahari, Dato Seri Robaayah, Wu, Delon Wu, Ardissino, Diego, Raev, Dimitar, Kremastinos, Dimitrios, Weaver, Douglas, Paolasso, Ernesto, Giannitsis, Evangelos, Verheugt, Freek, Maurer, Gerald, Katus, Hugo, Emanuelsson, Hakan, Horrow, Jay, Bassand, Jean-Pierre, Spinar, Jindrich, Morais, Joao, Lopez Sendon, Jose, Nicolau, Jose, Seung, Ki-Bae, Teik, Lim Soo, Heras, Magda, Claeys, Marc J., Sabatine, Marc, Vintila, Marius, Ruda, Mikhail, Thorsen, Mona, Kleiman, Neil, Babilonia, Noe, Commerford, Patrick, Gurbel, Paul, Aylward, Phil, Steg, Philippe Gabriel, Theroux, Pierre, Sritara, Piyamitr, Pais, Prem, Becker, Richard, Lassila, Riitta, Harrington, Robert A., Gao, Runlin, Husted, Steen, Duris, Tibor, Chapichadze, Zaza, HUS Comprehensive Cancer Center, University Management, Department of Oncology, and PLATO Investigators

Subjects
Male, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Comorbidity, 030204 cardiovascular system & hematology, urologic and male genital diseases, FUNCTION PROFILES, RESPONSIVENESS, Electrocardiography, 0302 clinical medicine, Risk Factors, Coronary Heart Disease, ARTERY-DISEASE, Medicine, Cardiac and Cardiovascular Systems, 030212 general & internal medicine, Myocardial infarction, Stroke, Original Research, Kardiologi, Absolute risk reduction, Diabetes, Type 2, DUAL ANTIPLATELET THERAPY, Middle Aged, Prognosis, Clopidogrel, female genital diseases and pregnancy complications, 3. Good health, Survival Rate, diabetes mellitus, Female, Cardiology and Cardiovascular Medicine, Ticagrelor, medicine.drug, Platelets, RENAL-FUNCTION, medicine.medical_specialty, Acute coronary syndrome, ANTITHROMBOTIC THERAPY, INHIBITION, acute coronary syndrome, ticagrelor, 03 medical and health sciences, Internal medicine, Diabetes mellitus, Humans, Renal Insufficiency, Chronic, Aged, Retrospective Studies, Pharmacology, clopidogrel, Dose-Response Relationship, Drug, business.industry, Thrombosis, medicine.disease, United States, REACTIVITY, 3121 General medicine, internal medicine and other clinical medicine, Purinergic P2Y Receptor Antagonists, Human medicine, business, Acute Coronary Syndromes, Platelet Aggregation Inhibitors, chronic kidney disease, Follow-Up Studies, Kidney disease
Abstract

Background There are limited data on how the combination of diabetes mellitus ( DM ) and chronic kidney disease ( CKD ) affects cardiovascular outcomes as well as response to different P2Y 12 receptor antagonists, which represented the aim of the present investigation. Methods and Results In this post hoc analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial, which randomized acute coronary syndrome patients to ticagrelor versus clopidogrel, patients (n=15 108) with available DM and CKD status were classified into 4 groups: DM +/ CKD + (n=1058), DM +/ CKD − (n=2748), DM −/ CKD + (n=2160), and DM −/ CKD − (n=9142). The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke at 12 months. The primary safety end point was PLATO major bleeding. DM +/ CKD + patients had a higher incidence of the primary end point compared with DM −/ CKD − patients (23.3% versus 7.1%; adjusted hazard ratio 2.22; 95% CI 1.88–2.63; P DM +/ CKD − and DM −/ CKD + had an intermediate risk profile. The same trend was shown for the individual components of the primary end point and for major bleeding. Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across subgroups ( P ‐interaction=0.264), but with an increased absolute risk reduction in DM +/ CKD +. The effects on major bleeding were also consistent across subgroups ( P ‐interaction=0.288). Conclusions In acute coronary syndrome patients, a gradient of risk was observed according to the presence or absence of DM and CKD , with patients having both risk factors at the highest risk. Although the ischemic benefit of ticagrelor over clopidogrel was consistent in all subgroups, the absolute risk reduction was greatest in patients with both DM and CKD . Clinical Trial Registration URL : http://www.clinicatrials.gov . Unique identifier: NCT 00391872.

Published
2019

14. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET

Author

Kirsten Anne-Marie, Anne Wirz, Erich Traugott, Ficker Joachim H, Bertram J. Jobst, Vivien Janke, Stubbe Beate, Johanna I. Lutter, Barbara Ziss, Franziska C. Trudzinski, Patricia Berger, Henrik Watz, Gogol Manfred, Thomas Bahmer, Beate Polte, Kronsbein Juliane, Campus Kiel, Lange Christoph, Martina Seibert, Rudolf A. Jörres, Pfeifer Michael, Timmermann Hartmut, Grohé Christian, Tobias Welte, Studnicka Michael, Petra Hundack-Winter, Jana Graf, Jürgen Behr, Diana Schottel, Buhl Roland, Virchow J. Christian, Bewig Burkhard, Ruhrlandklinik gGmbH. Essen, Wirtz Hubert, Rosalie Untsch, Birte Struck, Peter Alter, Kathrin Kahnert, Gudrun Hübner, Vogelmeier Claus, Sabine Michalewski, Kropf-Sanchen Cornelia, Kenn Klaus, Pontus Mertsch, Sonja Rohweder, Hauck Rainer, Andreas Stefan, Ilona Kietzmann, Zabel Peter, Michaela Schrade-Illmann, Höffken Gerd, Julia Tobias, Frank Biertz, Seeger Werner, Manuel Klöser, Kahnert Kathrin, Teschler Helmut, Anita Reichel, Gina Spangel, Ulrike Rieber, Randerath Winfried J, Julia Teng, Tanja Lucke, Herth Felix, Jeanette Pieper, Lenka Krabbe, Taube Christian, Jürgen Biederer, Wagner Ulrich, Doris Lehnert, Claus Vogelmeier, Katrin Schwedler, Henke Markus, Jany Berthold, Katus Hugo A, Bals Robert, Zaklina Hinz, Cornelia Böckmann, Ellen Burmann, Margret Gleiniger, Behr Jürgen, Britta Markworth, Ewert Ralf, Gertraud Weiß, Katrin Wons, Barbara Arikan, Watz Henrik, Beate Schaufler, Lena Sterk, Robert Bals, Hans-Ulrich Kauczor, Koczulla Rembert, Held Matthias, and Welte Tobias

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Copd patients, Medizin, Comorbidity, Severity of Illness Index, Pulmonary Disease, Chronic Obstructive, Medicine, Humans, In patient, Lung, Aged, Aged, 80 and over, COPD, Bronchiectasis, business.industry, Phlegm, Middle Aged, medicine.disease, Radiological weapon, Clinical diagnosis, Cohort, Female, Radiography, Thoracic, Radiology, medicine.symptom, business, Tomography, X-Ray Computed
Abstract

Bronchiectasis (BE) might be frequently present in COPD but masked by COPD symptoms. We studied the relationship of clinical signs of bronchiectasis to the presence and extent of its radiological signs in patients of different COPD severity. Visit 4 data (GOLD grades 1-4) of the COSYCONET cohort was used. Chest CT scans were evaluated for bronchiectasis in 6 lobes using a 3-point scale (0: absence, 1: ≤50%, 2: >50% BE-involvement for each lobe). 1176 patients were included (61%male, age 67.3y), among them 38 (3.2%) with reported physicians' diagnosis of bronchiectasis and 76 (6.5%) with alpha1-antitrypsin deficiency (AA1D). CT scans were obtained in 429 patients. Within this group, any signs of bronchiectasis were found in 46.6% of patients, whereby ≤50% BE occurred in 18.6% in ≤2 lobes, in 10.0% in 3-4 lobes, in 15.9% in 5-6 lobes; >50% bronchiectasis in at least 1 lobe was observed in 2.1%. Scores ≥4 correlated with an elevated ratio FRC/RV. The clinical diagnosis of bronchiectasis correlated with phlegm and cough and with radiological scores of at least 3, optimally ≥5. In COPD patients, clinical diagnosis and radiological signs of BE showed only weak correlations. Correlations became significant with increasing BE-severity implying radiological alterations in several lobes. This indicates the importance of reporting both presence and extent of bronchiectasis on CT. Further research is warranted to refine the criteria for CT scoring of bronchiectasis and to determine the relevance of radiologically but not clinically detectible bronchiectasis and their possible implications for therapy in COPD patients.

Published
2020

15. CAT score single item analysis in patients with COPD: results from COSYCONET

Author

J. Randerath Winfried, Pfeifer Michael, Kenn Klaus, Joachim H. Ficker, Gogol Manfred, Grohé Christian, Höffken Gerd, Zaklina Hinz, Julia Tobias, Henke Markus, Teschler Helmut, Welte Tobias, Benjamin Waschki, Buhl Roland, Paul W. Jones, Kirsten Anne-Marie, A. Katus Hugo, Taube Christian, Bewig Burkhard, Beate Polte, Kronsbein Juliane, Stubbe Beate, Bals Robert, Johanna I. Lutter, Sarah Marietta von Siemens, Lange Christoph, Vogelmeier Claus, Ellen Burmann, Wirtz Hubert, Kathrin Kahnert, Erich Traugott, Behr Jürgen, Birte Struck, Vivien Janke, Lenka Krabbe, Timmermann Hartmut, Wagner Ulrich, Anita Reichel, Sabine Michalewski, Gudrun Hübner, Seeger Werner, Doris Lehnert, Jany Berthold, Kropf-Sanchen Cornelia, Sandra Söhler, Jeanette Pieper, Ulrike Rieber, Peter Alter, Herth Felix, Zabel Peter, Andreas Stefan, Koczulla Rembert, Held Matthias, Tobias Welte, Franziska C. Trudzinski, Patricia Berger, Kahnert Kathrin, Jana Graf, Jürgen Behr, Rosalie Untsch, Rudolf A. Jörres, Kornelia Speth, Britta Markworth, Ewert Ralf, Gertraud Weiß, Hans-Ulrich Kauczor, Claus Vogelmeier, Katrin Schwedler, Katrin Wons, Bertram J. Jobst, Barbara Arikan, Margret Gleiniger, Henrik Watz, Watz Henrik, Studnicka Michael, Beate Schaufler, Diana Schottel, Sonja Rohweder, Robert Bals, Ilona Kietzmann, Virchow J. Christian, Burkhard Bewig, Hauck Rainer, and Michaela Schrade-Illmann

Subjects
Pulmonary and Respiratory Medicine, Percentile, medicine.medical_specialty, Medizin, Diagnostic Techniques, Respiratory System, Single item, CAT score, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Internal medicine, medicine, COPD, In patient, 030212 general & internal medicine, Lung function, Emphysema, business.industry, Regression analysis, Cat Score, Copd, medicine.disease, Exploratory factor analysis, respiratory tract diseases, 030228 respiratory system, Cohort, business
Abstract

The COPD Assessment Test (CAT) is in widespread use for the evaluation of patients with chronic obstructive pulmonary disease (COPD). We assessed whether the CAT items carry additional information beyond the sum score regarding COPD characteristics including emphysema. Patients of GOLD grades 1 to 4 from the COPD cohort COSYCONET (German COPD and Systemic Consequences - Comorbidities Network) with complete CAT data were included (n = 2270), of whom 493 had chest CT evaluated for the presence of emphysema. Comorbidities and lung function were assessed following standardised procedures. Cross-sectional data analysis was based on multiple regression analysis of the single CAT items against a panel of comorbidities, lung function, or CT characteristics (qualitative score, 15th percentile of mean lung density), with age, BMI and gender as covariates. This was supported by exploratory factor analysis. Regarding the relationship to comorbidities and emphysema, there were marked differences between CAT items, especially items 1 and 2 versus 3 to 8. This grouping was basically confirmed by factor analysis. Items 4 and 5, and to a lower degree 1, 2 and 6, appeared to be informative regarding the presence of emphysema, whereas the total score was not or less informative. Regarding comorbidities, similar findings as for the total CAT score were obtained for the modified Medical Research Council scale (mMRC) which was also informative regarding emphysema. Our findings suggest that the usefulness of the CAT can be increased if evaluated on the basis of single items which may be indicating the presence of comorbidities and emphysema.

Published
2020

16. Supplemental_Table_1 - Quantitative Efficacy and Fate of Mesenchymal Stromal Cells Targeted to Cardiac Sites by Radiofrequency Catheter Ablation

Author

Malik, Rizwan, Darche, Fabrice A., Rivinius, Rasmus, Seckinger, Anja, Krause, Ulf, Koenen, Michael, Thomas, Dierk, Katus, Hugo A., and Schweizer, Patrick A.

Subjects
Medicine, Cell Biology
Abstract

Supplemental_Table_1 for Quantitative Efficacy and Fate of Mesenchymal Stromal Cells Targeted to Cardiac Sites by Radiofrequency Catheter Ablation by Rizwan Malik, Fabrice A. Darche, Rasmus Rivinius, Anja Seckinger, Ulf Krause, Michael Koenen, Dierk Thomas, Hugo A. Katus and Patrick A. Schweizer in Cell Transplantation

Published
2020
Full Text
View/download PDF

17. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Author

Hindricks, Gerhard, Potpara, Tatjana, Dagres, Nikolaos, Arbelo, Elena, Bax, Jeroen J, Blomström-Lundqvist, Carina, Boriani, Giuseppe, Castella, Manuel, Dan, Gheorghe-Andrei, Dilaveris, Polychronis E, Fauchier, Laurent, Filippatos, Gerasimos, Kalman, Jonathan M, La Meir, Mark, Lane, Deirdre A, Lebeau, Jean-Pierre, Lettino, Maddalena, Lip, Gregory Y H, Pinto, Fausto J, Thomas, G Neil, Valgimigli, Marco, Van Gelder, Isabelle C, Van Putte, Bart P, Watkins, Caroline L, Kirchhof, Paulus, Kühne, Michael, Aboyans, Victor, Ahlsson, Anders, Balsam, Pawel, Bauersachs, Johann, Benussi, Stefano, Brandes, Axel, Braunschweig, Frieder, Camm, A John, Capodanno, Davide, Casadei, Barbara, Conen, David, Crijns, Harry J G M, Delgado, Victoria, Dobrev, Dobromir, Drexel, Heinz, Eckardt, Lars, Fitzsimons, Donna, Folliguet, Thierry, Gale, Chris P, Gorenek, Bulent, Haeusler, Karl Georg, Heidbuchel, Hein, Iung, Bernard, Katus, Hugo A, Kotecha, Dipak, Landmesser, Ulf, Leclercq, Christophe, Lewis, Basil S, Mascherbauer, Julia, Merino, Jose Luis, Merkely, Béla, Mont, Lluís, Mueller, Christian, Nagy, Klaudia V, Oldgren, Jonas, Pavlović, Nikola, Pedretti, Roberto F E, Petersen, Steffen E, Piccini, Jonathan P, Popescu, Bogdan A, Pürerfellner, Helmut, Richter, Dimitrios J, Roffi, Marco, Rubboli, Andrea, Scherr, Daniel, Schnabel, Renate B, Simpson, Iain A, Shlyakhto, Evgeny, Sinner, Moritz F, Steffel, Jan, Sousa-Uva, Miguel, Suwalski, Piotr, Svetlosak, Martin, Touyz, Rhian M, Neil Thomas, G, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Cardiovascular Centre (CVC), Surgical clinical sciences, and Cardiac Surgery

Subjects
left atrial ablation, left atrial appendage occlusion, AF surgery, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Management of atrial fibrillation, 030204 cardiovascular system & hematology, Cardioversion, VITAMIN-K ANTAGONIST, surgery, chemistry.chemical_compound, 0302 clinical medicine, cardioversion, Edoxaban, QUALITY-OF-LIFE, antiarrhythmic drugs, OBSTRUCTIVE SLEEP-APNEA, catheter ablation, RADIOFREQUENCY CATHETER ABLATION, Medicine, atrial fibrillation, 030212 general & internal medicine, anticoagulation, reproductive and urinary physiology, ComputingMilieux_MISCELLANEOUS, pulmonary vein isolation, 0303 health sciences, rhythm control, EACTS, HEART RHYTHM SOCIETY, recommendations, Atrial fibrillation, General Medicine, non-Vitamin K antagonist oral anticoagulants, Vitamin K antagonist, PULMONARY-VEIN ISOLATION, stroke, 3. Good health, 2020 ESC Guidelines, Dronedarone, vitamin K antagonists, Cardiothoracic surgery, Cardio-Thoracic Surgery, embryonic structures, DIRECT ORAL ANTICOAGULANTS, cardiovascular system, Cardiology, Dose reduction, biological phenomena, cell phenomena, and immunity, Cardiology and Cardiovascular Medicine, medicine.drug, Quinidine, medicine.medical_specialty, medicine.drug_class, non-vitamin K antagonist oral anticoagulants, PERCUTANEOUS CORONARY INTERVENTION, Renal function, macromolecular substances, ABC pathway, Guidelines, rate control, screening, upstream therapy, Vitamin K antagonists, B700, 03 medical and health sciences, Internal medicine, Diseases of the circulatory (Cardiovascular) system, cardiovascular diseases, 030304 developmental biology, urogenital system, business.industry, medicine.disease, TRANSIENT ISCHEMIC ATTACK, ANTIARRHYTHMIC-DRUG-THERAPY, chemistry, 030228 respiratory system, Concomitant, RC666-701, business
Abstract

Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight

Published
2021

18. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort

Author

F.C. Trudzinski, K. Kahnert, C.F. Vogelmeier, P. Alter, F. Seiler, S. Fähndrich, H. Watz, T. Welte, T. Speer, S. Zewinger, F. Biertz, H.-U. Kauczor, R.A. Jörres, R. Bals, Andreas Stefan, Bals Robert, Behr Jürgen, Kahnert Kathrin, Bewig Burkhard, Buhl Roland, Ewert Ralf, Stubbe Beate, Ficker Joachim H, Gogol Manfred, Grohé Christian, Hauck Rainer, Held Matthias, Jany Berthold, Henke Markus, Herth Felix, Höffken Gerd, Katus Hugo A, Kirsten Anne-Marie, Watz Henrik, Koczulla Rembert, Kenn Klaus, Kronsbein Juliane, Kropf-Sanchen Cornelia, Lange Christoph, Zabel Peter, Pfeifer Michael, Randerath Winfried J, null eeger Werner, Studnicka Michael, Taube Christian, Teschler Helmut, Timmermann Hartmut, Virchow J. Christian, Vogelmeier Claus, Wagner Ulrich, Welte Tobias, and Wirtz Hubert

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Exacerbation, Partial Pressure, Medizin, Renal function, Comorbidity, Acid-Base Imbalance, Kidney Function Tests, Risk Assessment, Cohort Studies, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, DLCO, Diffusing capacity, Internal medicine, Forced Expiratory Volume, medicine, Humans, Respiratory function, 030212 general & internal medicine, Aged, COPD, Carbon Monoxide, business.industry, Middle Aged, medicine.disease, respiratory tract diseases, Respiratory Function Tests, Cross-Sectional Studies, 030228 respiratory system, Cohort, Cardiology, Disease Progression, Pulmonary Diffusing Capacity, Female, Blood Gas Analysis, Risk assessment, business, Glomerular Filtration Rate
Abstract

Rationale Alterations of acid-base metabolism are an important outcome predictor in acute exacerbations of COPD, whereas sufficient metabolic compensation and adequate renal function are associated with decreased mortality. In stable COPD there is, however, only limited information on the combined role of acid-base balance, blood gases, renal and respiratory function on exacerbation risk grading. Methods We used baseline data of the COPD cohort COSYCONET, applying linear and logistic regression analyses, the results of which were implemented into a comprehensive structural equation model. As most informative parameters it comprised the estimated glomerular filtration rate (eGFR), lung function defined via forced expiratory volume in 1 s (FEV1), intrathoracic gas volume (ITGV) and (diffusing capacity for carbon monoxide (DLCO), moreover arterial oxygen content (CaO2), partial pressure of oxygen (PaCO2), base exess (BE) and exacerbation risk according to GOLD criteria. All measures were adjusted for age, gender, body-mass index, the current smoking status and pack years. Results 1506 patients with stable COPD (GOLD grade 1–4; mean age 64.5 ± 8.1 y; mean FEV1 54 ± 18 %predicted, mean eGFR 82.3 ± 16.9 mL/min/1.73 m2) were included. BE was linked to eGFR, lung function and PaCO2 and played a role as indirect predictor of exacerbation risk via these measures; moreover, eGFR was directly linked to exacerbation risk. These associations remained significant after taking into account medication (diuretics, oral and inhaled corticosteroids), whereby corticosteroids had effects on exacerbation risk and lung function, diuretics on eGFR, BE and lung function. Conclusion Even in stable COPD acid-base metabolism plays a key integrative role in COPD risk assessment despite rather small deviations from normality. It partially mediates the effects of impairments in kidney function, which are also directly linked to exacerbation risk.

Published
2019

19. Additional file 1: of Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis

Author

Arenja, Nisha, Andre, Florian, Riffel, Johannes, Siepen, Fabian, Hegenbart, Ute, Schรถnland, Stefan, Kristen, Arnt, Katus, Hugo, and Buss, Sebastian

Subjects
embryonic structures, cardiovascular system, cardiovascular diseases
Abstract

Table S6. Late Gadolinium Enhancement (LGE) pattern analysis. Table S7. CMR data of patients with light-chain amyloidosis compared to different Late Gadolinium Enhancement (LGE) distribution groups (DOCX 31 kb)

Published
2019
Full Text
View/download PDF

20. Painful Hand Swelling after a Roller Coaster Ride

Author

Radeleff Boris, Müller Oliver J, Vogel Britta, Stoll Felicitas, and Katus Hugo A

Subjects
medicine.medical_specialty, Painful hand, business.industry, Physical therapy, medicine, General Medicine, Roller coaster, Swelling, medicine.symptom, business
Published
2018

21. [2017 ESC/EACTS Guidelines for the management of valvular heart disease]

Author

Baumgartner, Helmut, Falk, Volkmar, Bax, Jeroen J., De Bonis, Michele, Hamm, Christian, Holm, Per Johan, Iung, Bernard, Lancellotti, Patrizio, Lansac, Emmanuel, Muã±oz, Daniel Rodriguez, Rosenhek, Raphael, Sjã¶gren, Johan, Tornos Mas, Pilar, Vahanian, Alec, Walther, Thomas, Wendler, Olaf, Windecker, Stephan, Zamorano, Jose Luis, Roffi, Marco, Alfieri, Ottavio, Agewall, Stefan, Ahlsson, Anders, Barbato, Emanuele, Bueno, Hector, Collet, Jean-philippe, Coman, Ioan Mircea, Czerny, Martin, Delgado, Victoria, Fitzsimons, Donna, Folliguet, Thierry, Gaemperli, Oliver, Habib, Gilbert, Harringer, Wolfgang, Haude, Michael, Hindricks, Gerhard, Katus, Hugo A., Knuuti, Juhani, Kolh, Philippe, Leclercq, Christophe, Mcdonagh, Theresa A., Piepoli, Massimo Francesco, Pierard, Luc A., Ponikowski, Piotr, Rosano, Giuseppe M. C., Ruschitzka, Frank, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-uva, Miguel, Stepinska, Janina, Tarantini, Giuseppe, Tche, Didier, Aboyans, Victor, Unité de Recherche sur les Maladies Infectieuses Tropicales Emergentes (URMITE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Baumgartner, Helmut, Falk, Volkmar, Bax, Jeroen J., DE BONIS, Michele, Hamm, Christian, Johan Holm, Per, Iung, Bernard, Lancellotti, Patrizio, Lansac, Emmanuel, Rodriguez Munoz, Daniel, Rosenhek, Raphael, Sjögren, Johan, Tornos Mas, Pilar, Vahanian, Alec, Walther, Thoma, Wendler, Olaf, Windecker, Stephan, Luis Zamorano, Jose, Scientific Document Group, Esc, Bax, Jeroen J, De Bonis, Michele, Holm, Per Johan, Muñoz, Daniel Rodriguez, Zamorano, Jose Lui, Barbato, Emanuele, Zamorano, Jose Luis, Bonis, Michele De, Munoz, Daniel Rodriguez, Mas, Pilar Torno, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Muñoz, Daniel Rodríguez, and Zamorano, José Luis

Subjects
Male, Aortic stenosi, Valve surgery, Percutaneous valve intervention, Heart Valve Diseases, Tricuspid regurgitation, Guideline, 030204 cardiovascular system & hematology, 0302 clinical medicine, operacje zastawkowe, Valvular disease, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, protezy zastawkowe, 030212 general & internal medicine, Disease management (health), 610 Medicine & health, ComputingMilieux_MISCELLANEOUS, Societies, Medical, Heart Valve Prosthesis Implantation, Aged, 80 and over, Mitral stenosis, valvular heart disease, wytyczne, Disease Management, General Medicine, Middle Aged, Europe, niedomykalność trójdzielna, Prosthetic heart valve, Cardiology, Transcatheter mitral valve repair, Female, Cardiology and Cardiovascular Medicine, Aortic regurgitation, Aortic stenosis, Guidelines, Mitral regurgitation, Prosthetic heart valves, Tricuspid stenosis, Valve disease, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, MEDLINE, wady zastawkowe, stenoza aortalna, 03 medical and health sciences, Mitral valve stenosis, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Humans, Mitral stenosi, Intensive care medicine, Symptomatic aortic stenosis, przezskórne interwencje zastawkowe, Aged, Tricuspid stenosi, business.industry, stenoza mitralna, niedomykalność aortalna, ta3121, medicine.disease, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, niedomykalność mitralna, Surgery, stenoza trójdzielna, business
Abstract

International audience

Published
2017

22. Combined non-invasive assessment of endothelial shear stress and molecular imaging of inflammation for the prediction of inflamed plaque in hyperlipidaemic rabbit aortas

Author

Gitsioudis, Gitsios, Chatzizisis, Yiannis S, Wolf, Peter, Missiou, Anna, Antoniadis, Antonios P, Mitsouras, Dimitrios, Bartling, Sönke, Arica, Zeynep, Stuber, Matthias, Rybicki, Frank J, Nunninger, Max, Erbel, Christian, Libby, Peter, Giannoglou, George D, Katus, Hugo A, and Korosoglou, Grigorios

Subjects
Male, Computed Tomography Angiography, Biopsy, Hyperlipidemias, Bioengineering, Cardiorespiratory Medicine and Haematology, Sensitivity and Specificity, Random Allocation, Predictive Value of Tests, Vascular, Needle, Confidence Intervals, Animals, magnetic resonance imaging, endothelial shear stress, Endothelium, Aorta, Ultrasonography, Plaque, Atherosclerotic, Inflammation, Observer Variation, Interventional, Animal, Reproducibility of Results, molecular imaging, Atherosclerosis, Immunohistochemistry, ROC Curve, Cardiovascular System & Hematology, Disease Models, Disease Progression, Linear Models, hyperlipidaemic rabbits, Biomedical Imaging, Rabbits, Shear Strength
Abstract

AimsTo evaluate the incremental value of low endothelial shear stress (ESS) combined with high-resolution magnetic resonance imaging (MRI)- and computed tomography angiography (CTA)-based imaging for the prediction of inflamed plaque.Methods and resultsTwelve hereditary hyperlipidaemic rabbits underwent quantitative analysis of plaque in the thoracic aorta with 256-slice CTA and USPIO-enhanced (ultra-small superparamagnetic nanoparticles, P904) 1.5-T MRI at baseline and at 6-month follow-up. Computational fluid dynamics using CTA-based 3D reconstruction of thoracic aortas identified the ESS patterns in the convex and concave curvature subsegments of interest. Subsegments with low baseline ESS exhibited significant increase in wall thickness and plaque inflammation by MRI, in non-calcified plaque burden by CTA, and developed increased plaque size, lipid and inflammatory cell accumulation (high-risk plaque features) at follow-up by histopathology. Multiple regression analysis identified baseline ESS and inflammation by MRI to be independent predictors of plaque progression, while receiver operating curve analysis revealed baseline ESS alone or in combination with inflammation by MRI as the strongest predictor for augmented plaque burden and inflammation (low ESS at baseline: AUC = 0.84, P < 0.001; low ESS and inflammation by molecular MRI at baseline: AUC = 0.89, P < 0.001).ConclusionLow ESS predicts progression of plaque burden and inflammation as assessed by non-invasive USPIO-enhanced MRI. Combined non-invasive assessment of ESS and imaging of inflammation may serve to predict plaque with high-risk features.

Published
2017

26. Additional file 11: of Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells

Author

Schweizer, Patrick, Darche, Fabrice, Ullrich, Nina, Geschwill, Pascal, Greber, Boris, Rivinius, Rasmus, Seyler, Claudia, MĂźller-Decker, Karin, Draguhn, Andreas, Utikal, Jochen, Koenen, Michael, Katus, Hugo, and Thomas, Dierk

Abstract

Electrophysiological characterization of action potentials (APs) recorded from early differentiated iPSC-derived cells (dhiPSC, age 10Â days) by current clamp technique. (DOC 29 kb)

Published
2017
Full Text
View/download PDF

27. A Self-Taught Artificial Agent for Multi-Physics Computational Model Personalization

Author

Neumann, Dominik, Mansi, Tommaso, Itu, Lucian, Georgescu, Bogdan, Kayvanpour, Elham, Sedaghat-Hamedani, Farbod, Amr, Ali, Haas, Jan, Katus, Hugo, Meder, Benjamin, Steidl, Stefan, Hornegger, Joachim, and Comaniciu, Dorin

Subjects
Computational Engineering, Finance, and Science (cs.CE), FOS: Computer and information sciences, Artificial Intelligence (cs.AI), Computer Science - Artificial Intelligence, Computer Science - Computational Engineering, Finance, and Science
Abstract

Personalization is the process of fitting a model to patient data, a critical step towards application of multi-physics computational models in clinical practice. Designing robust personalization algorithms is often a tedious, time-consuming, model- and data-specific process. We propose to use artificial intelligence concepts to learn this task, inspired by how human experts manually perform it. The problem is reformulated in terms of reinforcement learning. In an off-line phase, Vito, our self-taught artificial agent, learns a representative decision process model through exploration of the computational model: it learns how the model behaves under change of parameters. The agent then automatically learns an optimal strategy for on-line personalization. The algorithm is model-independent; applying it to a new model requires only adjusting few hyper-parameters of the agent and defining the observations to match. The full knowledge of the model itself is not required. Vito was tested in a synthetic scenario, showing that it could learn how to optimize cost functions generically. Then Vito was applied to the inverse problem of cardiac electrophysiology and the personalization of a whole-body circulation model. The obtained results suggested that Vito could achieve equivalent, if not better goodness of fit than standard methods, while being more robust (up to 11% higher success rates) and with faster (up to seven times) convergence rate. Our artificial intelligence approach could thus make personalization algorithms generalizable and self-adaptable to any patient and any model., Comment: Submitted to Medical Image Analysis, Elsevier

Published
2016
Full Text
View/download PDF

28. Additional file 1: Table S1. of Quantification of myocardial deformation in children by cardiovascular magnetic resonance feature tracking: determination of reference values for left ventricular strain and strain rate

Author

AndrĂŠ, Florian, DaniĂŤlle Robbers-Visser, Helling-Bakki, Astrid, FĂśll, Angela, Voss, Andreas, Katus, Hugo, Helbing, Willem, Buss, Sebastian, and Eichhorn, Joachim

Abstract

Centiles of the global peak longitudinal endocardial systolic strain derived only from 4-chamber views. Table S2. Centiles of the global peak longitudinal epicardial systolic strain derived only from 4-chamber views. Table S3. Centiles of the early peak longitudinal endocardial diastolic strain rate derived only from 4-chamber views. Table S4. Centiles of the early peak longitudinal epicardial diastolic strain rate derived only from 4-chamber views. (PDF 654Â kb)

Published
2016
Full Text
View/download PDF

29. Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy

Author

Heinig, Matthias, Adriaens, Michiel E., Schafer, Sebastian, Deutekom, Hanneke W. M. Van, Lodder, Elisabeth M., Ware, James S., Schneider, Valentin, Felkin, Leanne E., Creemers, Esther E., Meder, Benjamin, Katus, Hugo A., Ruehle, Frank, Stoll, Monika, Cambien, Francois, Villard, Eric, Charron, Philippe, Varro, Andras, Bishopric, Nanette H., George, Alfred L., Remedios, Cristobal Dos, Moreno-Moral, Aida, Pesce, Francesco, Bauerfeind, Anja, Rueschendorf, Franz, Rintisch, Carola, Petretto, Enrico, Barton, Paul J., Cook, Stuart A., Pinto, Yigal M., Bezzina, Connie R., and Hubner, Norbert

Subjects
500 Naturwissenschaften und Mathematik::570 Biowissenschaften, Biologie::576 Genetik und Evolution, FOS: Biological sciences, Genetics, Dilated cardiomyopathy, Heart, Gene expression, eQTL, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit, 3. Good health
Abstract

Background: Genetic variation is an important determinant of RNA transcription and splicing, which in turn contributes to variation in human traits, including cardiovascular diseases. Results: Here we report the first in-depth survey of heart transcriptome variation using RNA-sequencing in 97 patients with dilated cardiomyopathy and 108 non-diseased controls. We reveal extensive differences of gene expression and splicing between dilated cardiomyopathy patients and controls, affecting known as well as novel dilated cardiomyopathy genes. Moreover, we show a widespread effect of genetic variation on the regulation of transcription, isoform usage, and allele-specific expression. Systematic annotation of genome-wide association SNPs identifies 60 functional candidate genes for heart phenotypes, representing 20% of all published heart genome-wide association loci. Focusing on the dilated cardiomyopathy phenotype we found that eQTL variants are also enriched for dilated cardiomyopathy genome-wide association signals in two independent cohorts. Conclusions: RNA transcription, splicing, and allele-specific expression are each important determinants of the dilated cardiomyopathy phenotype and are controlled by genetic factors. Our results represent a powerful resource for the field of cardiovascular genetics.

30. Feasibility Study on Cardiac Arrhythmia Ablation Using High-Energy Heavy Ion Beams

Author

Rasmus Rivinius, Dierk Thomas, Susan B. Johnson, A. Constantinescu, Anna Eichhorn, Daniel Richter, Hugo A. Katus, S. Helmbrecht, Nadine Erbeldinger, Marco Durante, Claudia Fournier, Robert Kaderka, M. Prall, Christoph Bert, Douglas L. Packer, Christian Graeff, Kay D. Parker, Samuel J. Asirvatham, Ann Kathrin Rahm, Mitsuru Takami, Palma Simoniello, Jürgen Debus, Fine Fiedler, H. Immo Lehmann, Patrick Lugenbiel, Lehmann, H. Immo, Graeff, Christian, Simoniello, Palma, Constantinescu, Anna, Takami, Mitsuru, Lugenbiel, Patrick, Richter, Daniel, Eichhorn, Anna, Prall, Matthia, Kaderka, Robert, Fiedler, Fine, Helmbrecht, Stephan, Fournier, Claudia, Erbeldinger, Nadine, Rahm, Ann Kathrin, Rivinius, Rasmu, Thomas, Dierk, Katus, Hugo A, Johnson, Susan B, Parker, Kay D, Debus, Jürgen, Asirvatham, Samuel J, Bert, Christoph, Durante, Marco, and Packer, Douglas L.

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, Sus scrofa, Apoptosis, 030204 cardiovascular system & hematology, Article, Intracardiac injection, 030218 nuclear medicine & medical imaging, Pulmonary vein, Radiotherapy, High-Energy, Lesion, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Cardiac conduction, medicine, Animals, Multidisciplinary, business.industry, Myocardium, Ultrasound, Cardiac arrhythmia, Arrhythmias, Cardiac, Dose-Response Relationship, Radiation, Ablation, medicine.anatomical_structure, Ventricle, Positron-Emission Tomography, cardiovascular system, Cardiology, Female, medicine.symptom, business
Abstract

High-energy ion beams are successfully used in cancer therapy and precisely deliver high doses of ionizing radiation to small deep-seated target volumes. A similar noninvasive treatment modality for cardiac arrhythmias was tested here. This study used high-energy carbon ions for ablation of cardiac tissue in pigs. Doses of 25, 40, and 55 Gy were applied in forced-breath-hold to the atrioventricular junction, left atrial pulmonary vein junction, and freewall left ventricle of intact animals. Procedural success was tracked by (1.) in-beam positron-emission tomography (PET) imaging; (2.) intracardiac voltage mapping with visible lesion on ultrasound; (3.) lesion outcomes in pathohistolgy. High doses (40–55 Gy) caused slowing and interruption of cardiac impulse propagation. Target fibrosis was the main mediator of the ablation effect. In irradiated tissue, apoptosis was present after 3, but not 6 months. Our study shows feasibility to use high-energy ion beams for creation of cardiac lesions that chronically interrupt cardiac conduction.

Published
2016

31. High-mobility group box-1 in ischemia-reperfusion injury of the heart

Author

Marco Bianchi, Benjamin Funke, Florian Bea, Andrew Remppis, Martin Andrassy, Hans C. Volz, Ivan K. Lukic, John C. Igwe, Per M. Humpert, Stefan E. Hardt, Ziya Kaya, Peter P. Nawroth, Hugo A. Katus, Angelika Bierhaus, Sven T. Pleger, Sebastian N Eichberger, Sebastian J. Buss, Frank Autschbach, Heimo Mairbäurl, Andrassy, Martin, Volz, Hans C., Igwe, John C., Funke, Benjamin, Eichberger, Sebastian N., Kaya, Ziya, Buss, Sebastian, Autschbach, Frank, Pleger, Sven T., Lukic, Ivan K., Bea, Florian, Hardt, Stefan E., Humpert, Per M., Bianchi, MARCO EMILIO, Mairbã¤url, Heimo, Nawroth, Peter P., Remppis, Andrew, Katus, Hugo A., and Bierhaus, Angelika

Subjects
Advanced Glycosylation End Product-Specific Receptor, Macrophage, Receptor for Advanced Glycation End Products, Ischemia, Myocardial Ischemia, chemical and pharmacologic phenomena, Inflammation, Pharmacology, HMGB1, Article, RAGE (receptor), Mice, Physiology (medical), Medicine, Animals, HMGB1 Protein, Receptors, Immunologic, Hypoxia, Receptor, Cells, Cultured, Mice, Knockout, biology, Animal, business.industry, Kinase, Reverse Transcriptase Polymerase Chain Reaction, Macrophages, Recombinant Protein, Hypoxia (medical), medicine.disease, Immunohistochemistry, Recombinant Proteins, Up-Regulation, Mice, Inbred C57BL, Myocardial infarction, Echocardiography, Reperfusion Injury, Reperfusion, Immunology, biology.protein, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Reperfusion injury, Protein Binding, Signal Transduction
Abstract

Background— High-mobility group box-1 (HMGB1) is a nuclear factor released by necrotic cells and by activated immune cells. HMGB1 signals via members of the toll-like receptor family and the receptor for advanced glycation end products (RAGE). Although HMGB1 has been implicated in ischemia/reperfusion (I/R) injury of the liver and lung, its role in I/R injury of the heart remains unclear. Methods and Results— Here, we demonstrate that HMGB1 acts as an early mediator of inflammation and organ damage in I/R injury of the heart. HMGB1 levels were already elevated 30 minutes after hypoxia in vitro and in ischemic injury of the heart in vivo. Treatment of mice with recombinant HMGB1 worsened I/R injury, whereas treatment with HMGB1 box A significantly reduced infarct size and markers of tissue damage. In addition, HMGB1 inhibition with recombinant HMGB1 box A suggested an involvement of the mitogen-activated protein kinases jun N-terminal kinase and extracellular signal-regulated kinase 1/2, as well as the nuclear transcription factor nuclear factor-κB in I/R injury. Interestingly, infarct size and markers of tissue damage were not affected by administration of recombinant HMGB1 or HMGB1 antagonists in RAGE −/− mice, which demonstrated significantly reduced damage in reperfused hearts compared with wild-type mice. Coincubation studies using recombinant HMGB1 in vitro induced an inflammatory response in isolated macrophages from wild-type mice but not in macrophages from RAGE −/− mice. Conclusions— HMGB1 plays a major role in the early event of I/R injury by binding to RAGE, resulting in the activation of proinflammatory pathways and enhanced myocardial injury. Therefore, blockage of HMGB1 might represent a novel therapeutic strategy in I/R injury.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results